INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 45h ago
HOUSE PTR5h ago
SEC 13F5h ago
ROBINHOOD CHAIN5h ago
SEC FORM 4/Grant or awardVerified data

Rucci Carolyn M. reported AKBA

SVP, Chief Legal Officer · Akebia Therapeutics, Inc. · Akebia Therapeutics, Inc. — Stock Option (Right to buy)

Side
A
Value
—
Shares
270.0K
Price
—
Executed
Jan 30, 2026
Disclosed
Feb 3, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jan 30 executedFeb 3, 2026 disclosed

AKBA · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · AKBA

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    15
    FR
    Frieson RonDirector
    AKBAAkebia Therapeutics, Inc.
    Grant or award
    		A—
    53.6K sh
    		Jun 17, 2026Jun 22, 2026
    traded Jun 17, 2026
    		+5dSEC FORM 4

    Evidence

    23
    FR
    Frieson RonDirector
    AKBAAkebia Therapeutics, Inc.
    Grant or award
    		A—
    35.7K sh
    		Jun 17, 2026Jun 22, 2026
    traded Jun 17, 2026
    		+5dSEC FORM 4

    Evidence

    10
    RM
    Rucci Carolyn M.SVP, Chief Legal Officer
    AKBAAkebia Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$38K
    27.5K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    17
    MC
    Malabre Richard CSVP, Chief Accounting Officer
    AKBAAkebia Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$50K
    36.1K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    10
    RM
    Rucci Carolyn M.SVP, Chief Legal Officer
    AKBAAkebia Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$23K
    16.8K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    10
    RM
    Rucci Carolyn M.SVP, Chief Legal Officer
    AKBAAkebia Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$35K
    25.4K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    10
    MC
    Malabre Richard CSVP, Chief Accounting Officer
    AKBAAkebia Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$19K
    13.4K sh
    		Feb 2, 2026Feb 4, 2026
    traded Feb 2, 2026
    		+2dSEC FORM 4

    Evidence

    17
    RM
    Rucci Carolyn M.SVP, Chief Legal Officer
    AKBAAkebia Therapeutics, Inc.
    Grant or award
    		A—
    190.0K sh
    		Jan 30, 2026Feb 3, 2026
    traded Jan 30, 2026
    		+4dSEC FORM 4

    Evidence

    9
    MC
    Malabre Richard CSVP, Chief Accounting Officer
    AKBAAkebia Therapeutics, Inc.
    Grant or award
    		A—
    119.0K sh
    		Jan 30, 2026Feb 3, 2026
    traded Jan 30, 2026
    		+4dSEC FORM 4

    Evidence

    17
    MC
    Malabre Richard CSVP, Chief Accounting Officer
    AKBAAkebia Therapeutics, Inc.
    Grant or award
    		A—
    79.0K sh
    		Jan 30, 2026Feb 3, 2026
    traded Jan 30, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002107264-26-000005
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 30, 2026
    Published
    Feb 3, 2026
    Ingested by INSIDER
    Nov 5, 04:19 UTC
    Last re-read
    Nov 5, 04:19 UTC

    Extracted facts

    Filer
    Rucci Carolyn M.
    Role
    SVP, Chief Legal Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Akebia Therapeutics, Inc. — Stock Option (Right to buy)
    Ticker
    AKBA
    Shares
    270.0K
    Price per share
    $0
    Execution date (reported)
    Jan 30, 2026
    Owned after transaction
    270.0K shares
    Days from execution to publication
    4

    What this establishes

    Rucci Carolyn M. filed this Form 4 reporting a grant or award of AKBA on Jan 30, 2026. It became public on Feb 3, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    SVP, Chief Legal Officer
    Rucci Carolyn M.cik:0002107264
    Issuer
    Akebia Therapeutics, Inc.cik:0001517022

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.